ALBANY
Seite 2 von 13 Neuester Beitrag: 25.04.21 01:14 | ||||
Eröffnet am: | 16.06.12 17:15 | von: buran | Anzahl Beiträge: | 319 |
Neuester Beitrag: | 25.04.21 01:14 | von: Christinatpxh. | Leser gesamt: | 44.323 |
Forum: | Hot-Stocks | Leser heute: | 6 | |
Bewertet mit: | ||||
Seite: < 1 | | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... 13 > |
Frankfurt 1.198 2,506 € 2,603 € 1.153 3,87% 13:29:37
Nasdaq 1.300 3,17 $ 3,45 $ 500 8,83% 10:02:01
.....wohl bekommmmmmms ;-)
Zeit Kurs Stück
15:55:35§2,75 €
0 §
15:55:01§2,743 €
0 §
15:54:52 2,754 €
0§
der Deutsche war heute auch faul "Schuldigung,ich hätte besser schreiben sollen der Ami hat sich schon die ersten Scheine in's Depot gezogen und cash zahlen lassen und nicht überwiegend gekauft und gepusht,ich nenne das aber trotzdem faul - aber ich hab mich dafür entschuldigt,buran
Handelsplatz Geld-Stk. GeldGeld-Brief BriefBrief-Stk.§Spread Zeit
Nasdaq 100 3,26 $ 4,00 $ 2.000 22,70% 15:02:27
__________________________________________________
so das derzeitige Angebot
Handelsplatz Geld-Stk. GeldGeld-Brief BriefBrief-Stk.§Spread Zeit
Nasdaq 100 3,26 $ 4,00 $ 2.000 22,70% 15:12:10
__________________________________________________
bittesehr das ist Dein Preis,buran
+1,11%
___________________________________________
jetzt kommt's unterm Strich,das was man nennt Bilanz
___________________________________________
ALBANY MOLEC. 2,724 € +1,11% Perf. seit Threadbeginn: +37,14%
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Gruss buran
.....Aktienanzahl§30,8 Mio. (Stand: 11.08.12) << auch mal ein Augenmerk wert
buran
Frankfurt 1.093 2,746 € 2,853 € 1.052 3,90% 15:15:45
Nasdaq 100 3,42 $ 4,00 $ 2.000 16,96% 15:16:38
.....und beide Plätze handelbar,also ansteuerbar
trotzdem wacker ;-)))
22:05 18.10.12
PR Newswire
ALBANY, N.Y., Oct. 18, 2012
ALBANY, N.Y., Oct. 18, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing Inc., whose parent company, Shire plc (LSE: SHP, NASDAQ: SHPGY), is a global company that focuses its business on behavioral health, gastro intestinal diseases, rare diseases and regenerative medicine. The agreement extends a previously existing agreement between the two companies. The terms of the agreement are confidential.
(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )
"We are pleased to extend this agreement with Shire," said Thomas E. D'Ambra, Ph.D., Chairman, President and Chief Executive Officer of AMRI. "Our partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities."
About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For press releases and additional information about the company, please visit www.amriglobal.com.
SOURCE AMRI
Quelle: PR Newswire
13:05 30.10.12
PR Newswire
ALBANY, N.Y., Oct. 30, 2012
ALBANY, N.Y., Oct. 30, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue third quarter financial results before the opening of the market on Tuesday, November 6, 2012. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET.
(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)
The conference call can be accessed by dialing 888-364-3108 (domestic calls) or 719-457-2645 (international calls) at 9:45 a.m. ET and entering passcode 8248928. The webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at www.amriglobal.com/investor_relations/.
About AMRI
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development.
SOURCE AMRI
Quelle: PR Newswire
Frankfurt 1.074 2,794 € 2,902 € 1.034 3,87% 10:08:58
__________________________________________________
..bitte slebst wählen,GrB